Document Detail

Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
MedLine Citation:
PMID:  22901846     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the direct effect that GnRH analogues leuprolide acetate and cetrorelix acetate have on extracellular matrix in human leiomyoma and patient-matched myometrial cells.
DESIGN: Laboratory study.
SETTING: University hospital.
INTERVENTION(S): Cell culture, proliferation studies, and messenger RNA and protein analysis.
MAIN OUTCOME MEASURE(S): Expression of GnRHR1, COL1A1, fibronectin, and versican variant V0 in treated leiomyoma cells and patient-matched myometrial cells.
RESULT(S): Leiomyoma cells were treated with GnRH analogues for 6, 24, and 120 hours. Leuprolide treatment for 6 hours resulted in an increase in expression of GnRHR1 (4.02 ± 0.12-fold), COL1A1 (6.41 ± 0.29-fold), fibronectin (9.69 ± 0.18-fold), and versican variant V0 (7.58 ± 0.43-fold). Leiomyoma cells treated with cetrorelix for 6 hours showed a decreased expression of GnRHR1 (0.5 ± 0.15-fold), COL1A1 (3.79 ± 0.7-fold), fibronectin (0.92 ± 0.09-fold), and versican variant V0 (0.14 ± 0.07-fold). Leuprolide treatment of leiomyoma cells at high concentrations (10(-5) M) did not result in an increase in protein production. Cetrorelix treatment of leiomyoma cells for 6 hours showed an increase in fibronectin protein production (3.14 ± 0.09-fold). Protein production of leiomyoma cells treated with cetrorelix for 120 hours demonstrated a decrease in GnRHR1 (0.51 ± 0.07-fold), COL1A1 (0.35 ± 0.07-fold), fibronectin (1.94 ± 0.08-fold), and versican variant V0 (0.77 ± 0.19-fold).
CONCLUSION(S): Our findings demonstrate that GnRH analogue treatment directly regulated COL1A1, fibronectin, and matrix proteoglycan production. The reduction in versican variant V0 gene expression caused by cetrorelix treatment, and its association with the osmotic regulation of leiomyomas, presents a new and innovative approach to therapy for this disease.
Joy Lynne Britten; Minnie Malik; Gary Levy; Mirian Mendoza; William H Catherino
Related Documents :
10859526 - Microdissection of tissue sections: application to the molecular genetic characterisati...
22498826 - Immunohistochemistry-based cell cycle detection (iccd): a novel system to visualize cel...
16096966 - Epidermal differentiation: trichomes in arabidopsis as a model system.
20817616 - Atypical cadherins dachsous and fat control dynamics of noncentrosomal microtubules in ...
12647936 - Characterization of heterokaryons between skeletal myoblasts and preadipocytes: myogeni...
5784196 - Dextran-induced agglutination of streptococcus mutans, and its potential role in the fo...
Publication Detail:
Type:  Journal Article; Video-Audio Media     Date:  2012-08-14
Journal Detail:
Title:  Fertility and sterility     Volume:  98     ISSN:  1556-5653     ISO Abbreviation:  Fertil. Steril.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2013-01-03     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1299-307     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / pharmacology*
Cell Proliferation / drug effects
Collagen Type I / biosynthesis
Dose-Response Relationship, Drug
Extracellular Matrix Proteins / biosynthesis*,  genetics
Fibronectins / biosynthesis
Gene Expression Regulation, Neoplastic / drug effects
Gonadotropin-Releasing Hormone / agonists*,  analogs & derivatives*,  antagonists & inhibitors*,  metabolism,  pharmacology
Hormone Antagonists / pharmacology*
Leiomyoma / genetics,  metabolism*,  pathology
Leuprolide / pharmacology*
RNA, Messenger / metabolism
Receptors, LHRH / drug effects,  genetics,  metabolism
Time Factors
Tumor Cells, Cultured
Uterine Neoplasms / genetics,  metabolism*,  pathology
Versicans / biosynthesis
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Collagen Type I; 0/Extracellular Matrix Proteins; 0/Fibronectins; 0/GNRHR protein, human; 0/Hormone Antagonists; 0/RNA, Messenger; 0/Receptors, LHRH; 0/VCAN protein, human; 0/collagen type I, alpha 1 chain; 126968-45-4/Versicans; 33515-09-2/Gonadotropin-Releasing Hormone; 53714-56-0/Leuprolide; OON1HFZ4BA/cetrorelix

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does the metabolic syndrome predict subclinical atherosclerotic damage in an asymptomatic population...
Next Document:  Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression...